About Chronic Obstructive Pulmonary Disease (COPD)
COPD is a chronic disease condition with a combination of symptoms of both chronic bronchitis and emphysema. Chronic bronchitis results in inflammation in the bronchioles, which results in increased mucus production. The condition is usually associated with a long-term cough with mucus. Emphysema results in the destruction of the walls of the alveoli, resulting in difficulty in breathing.
Technavio’s analysts forecast the global chronic obstructive pulmonary disease (COPD) drugs market to grow at a CAGR of 4.85% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global chronic obstructive pulmonary disease (COPD) drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat COPD.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Teva
Other prominent vendors
• Ache Laboratorios Farmaceuticos
• Almirall
• Aquinox Pharmaceuticals
• Ario Pharma
• Asmacure
• Astellas Pharma
• BioMarck Pharmaceuticals
• Chiesi Farmaceutici
• Cytokinetics
• F. Hoffmann-La Roche
• Gilead Sciences
• Innoviva
• Invion
• MediciNova
• Mereo BioPharma
• Mylan
• Orion Corporation
• Palobiofarma
• Pearl Therapeutics
• Pharmaxis
• Prosonix
• Pulmagen Therapeutics
• RespiVert
• SolAeroMed
• Sunovion Pharmaceuticals
• Theravance Biopharma
• Theron Pharmaceuticals
• Verona Pharma
• Xention
• Yungjin Pharm
• ZAI Lab
Market driver
• Uptake of LABA/LAMA combination therapies
• For a full, detailed list, view our report
Market challenge
• Negligence toward use of controller medications
• For a full, detailed list, view our report
Market trend
• Increased adoption of e-cigarettes and smoking cessation products
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Breakthrough in COPD research
• COPD: An overview
PART 05: Pipeline analysis
PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: Key buying criteria for COPD drugs
PART 08: Market segmentation by drug class
• Combination therapies
• Bronchodilators
• Steroids
• Leukotriene antagonists
• PDE-4 inhibitors
• Other medications
PART 09: Segmentation by ROA
• Inhalation
• Oral
PART 10: Drug delivery devices market for COPD drugs
• Market overview
• Market segmentation by product type
PART 11: Geographical segmentation
• Global COPD drugs market by geography 2015-2020
• COPD drugs market in Americas
• COPD drugs market in EMEA
• COPD drugs market in APAC
• COPD drugs market in China
PART 12: Market drivers
• Increase in smoking prevalence
• Uptake of LABA/LAMA combination therapies
• Robust pipeline with tentative approval of drugs
PART 13: Impact of drivers
PART 14: Market challenges
• Lack of innovation in pipeline molecules
• Negligence toward use of controller medications
• Low diagnosis rates
PART 15: Impact of drivers and challenges
PART 16: Market trends
• Innovative technologies for drug delivery
• Increased adoption of e-cigarettes and smoking cessation products
• Emergence of ultrasonic nebulizers
• Increase in online marketing services
• Growing use of home healthcare devices
PART 17: Vendor landscape
• Competitive scenario
• Key news
PART 18: Key vendor analysis
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Novartis
• Teva Pharmaceuticals
• Other prominent vendors
PART 19: Appendix
• List of abbreviations
PART 20: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Breakthrough research activities in field of COPD
Exhibit 03: Percentage share of pipeline molecules based on stage of development
Exhibit 04: Pipeline molecules based on MOA and stage of development
Exhibit 05: Percentage share of pipeline drugs based on MOA
Exhibit 06: Global COPD drugs market 2015-2020 ($ billions)
Exhibit 07: Global COPD drugs market snapshot: Developed and emerging markets 2015
Exhibit 08: Global COPD drugs market: Key parameters driving the market 2015
Exhibit 09: Five forces analysis
Exhibit 10: Key buying criteria for COPD drugs
Exhibit 11: Impact of key customer segments on global COPD drugs market
Exhibit 12: Segmentation of COPD drugs based on drug class
Exhibit 13: Percentage share of global COPD drugs by drug class based on revenue 2015
Exhibit 14: Global COPD drugs market: Drug class segmentation growth cycle analysis 2015
Exhibit 15: Combination therapies market in global COPD drugs market 2015-2020 ($ billions)
Exhibit 16: Bronchodilators market in global COPD drugs market 2015-2020 ($ billions)
Exhibit 17: Steroid drugs market in global COPD drugs market 2015-2020 ($ billions)
Exhibit 18: Leukotriene antagonists market in global COPD drugs market 2015-2020 ($ billions)
Exhibit 19: YoY growth and revenue of Daliresp 2012-2015 ($ billions)
Exhibit 20: Global COPD drugs market segmentation by drug class 2015
Exhibit 21: Segmentation of global COPD drugs market by ROA
Exhibit 22: Global COPD drug delivery devices market 2015-2020 ($ millions)
Exhibit 23: Global COPD devices market segmentation by product type
Exhibit 24: Percentage share of global COPD drug delivery devices by type 2015
Exhibit 25: Percentage share of inhalers in global COPD drug delivery devices market 2015
Exhibit 26: Inhalers market in global COPD drug-devices market 2015-2020 ($ millions)
Exhibit 27: Percentage share of nebulizers in global COPD drug delivery devices market by technology 2015
Exhibit 28: Nebulizers market in global COPD drug-devices market 2015-2020 ($ millions)
Exhibit 29: Global COPD drugs market by geography 2015-2020
Exhibit 30: Percentage share of global COPD drugs market by geography 2015 and 2020
Exhibit 31: Global COPD drugs market segmentation by geography 2015-2020 ($ billions)
Exhibit 32: Global share of COPD drugs market by geography 2015
Exhibit 33: COPD drugs market in Americas 2015-2020 ($ billions)
Exhibit 34: Prevalence rates of COPD in few countries of EMEA
Exhibit 35: COPD drugs market in EMEA 2015-2020 ($ billions)
Exhibit 36: COPD drugs market in APAC 2015-2020 ($ billions)
Exhibit 37: COPD drugs market in China 2015-2020 ($ billions)
Exhibit 38: Global COPD drugs market: Country analysis based on revenue and growth rate
Exhibit 39: Drug approvals in COPD drugs market in past three years (2014-2016)
Exhibit 40: Few COPD drug molecules in registration stage
Exhibit 41: Impact of drivers
Exhibit 42: Controller and rescue medications for the treatment of COPD
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Key vendors ranking 2015
Exhibit 45: Market share of key vendors based on revenues 2015
Exhibit 46: Geographical presence of key vendors
Exhibit 47: Competitive scenario of global COPD drugs market vendors 2015-2020
Exhibit 48: AstraZeneca: YoY revenue and growth rate of Symbicort 2013-2015 ($ billions)
Exhibit 49: AstraZeneca: Geographical segmentation of Symbicort 2015
Exhibit 50: AstraZeneca: YoY revenue and growth rate of Pulmicort 2013-2015 ($ millions)
Exhibit 51: AstraZeneca: Geographical segmentation of Pulmicort 2015
Exhibit 52: AstraZeneca: Metrics analysis
Exhibit 53: Boehringer Ingelheim: YoY revenue and growth rate of Spiriva 2013-2015 ($ billions)
Exhibit 54: Boehringer Ingelheim: Metrics analysis
Exhibit 55: GSK: YoY revenue and growth rate of Seretide/Advair 2013-2015 ($ billions)
Exhibit 56: Geographical segmentation of Seretide/Advair 2015
Exhibit 57: GSK: YoY revenue and growth rate of Flixotide/Flovent 2013-2015 ($ billions)
Exhibit 58: GSK: Geographical segmentation of Flixotide/Flovent 2015
Exhibit 59: GSK: YoY revenue and growth rate of Ventolin 2013-2015 ($ billions)
Exhibit 60: GSK: Geographical segmentation of Ventolin 2015
Exhibit 61: GSK: YoY growth and revenue of Relvar/Breo Ellipta 2014-2015 ($ millions)
Exhibit 62: GSK: Geographical segmentation of Relvar/Breo Ellipta 2015
Exhibit 63: GSK: YoY growth and revenue of Anoro Ellipta 2014-2015 ($ millions)
Exhibit 64: GSK: Geographical segmentation of Anoro Ellipta 2015
Exhibit 65: GSK: Metrics analysis
Exhibit 66: Novartis: YoY revenue and growth rate of Onbrez Breezhaler/Arcapta Neohaler 2014-2015 ($ millions)
Exhibit 67: Novartis: YoY revenue and growth rate of Seebri Breezhaler 2013-2015 ($ millions)
Exhibit 68: Novartis: YoY revenue and growth rate of Ultibro Breezhaler 2013-2015 ($ millions)
Exhibit 69: Novartis: Metrics analysis
Exhibit 70: Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)
Exhibit 71: Teva Pharmaceuticals: YoY revenue and growth rate of Qvar 2013-2015 ($ millions)
Exhibit 72: Teva Pharmaceuticals: Metrics analysis
